Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.
Perrigo (PRGO) shares are declining after a note from Jefferies (JEF) dampened expectations of an imminent sale of the drug manufacturer.
Mylan (MYL) shares are up after analysts at Bank of America (BAC) reiterated their 'buy' rating while raising its price target to $67.
Gentiva Health Services (GTVI) shares were up on Monday after Kindred Healtchare (KND) upped its price per share bid for a 14.9% stake in the company.
Exelixis (EXEL) shares are up over 20% in trading today after it announced positive results from its phase 3 advanced melanoma drug treatment.
Dublin-based drugs maker Shire said Monday it had entered "detailed discussions" with AbbVie about a $54 billion takeover proposal.
IsoRay (ISR) shares are climbing after the company's Cesium-131 internal radiation seeds were used in the world's first successful stereotactic brain implant surgery.
Healthcare investor David Miller believes Roche will likely acquire Exelixis in order to capture the full economics of the cancer drug cobimetinib.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Gentiva Health Service (GTIV) stock is climbing in pre-market trading after Kindred Healthcare (KND) upped their bid for the company to $16 per share from $14.50 per share.
Roche intends to seek U.S. approval for cobimetinib later this year.
BioAmber's "take-or-pay" deal with Vinmar this week, along with lower corn prices, is the start of big things to come for the sustainable chemical maker.
Allergan CEO is looking at potential sizable acquisitions as he seeks to fend off a $53 billion hostile takeover offer from Valeant Pharmaceuticals.
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV